Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;105(8):104174.
doi: 10.1016/j.labinv.2025.104174. Epub 2025 Apr 14.

Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome

Affiliations

Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome

Jingwei Li et al. Lab Invest. 2025 Aug.

Abstract

Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disorder predominantly caused by germline CXCR4 variants. Bone marrow (BM) evaluation showing myelokathexis helps to establish the diagnosis of WHIM syndrome, but unfamiliarity with pertinent diagnostic features and variability in morphologic and clinical findings may result in disease underrecognition. We aimed to characterize the clinical, BM, and peripheral blood (PB) features of 30 patients with germline CXCR4 variants, including genotype-phenotype analysis and correlation between morphologic features and functional CXCR4 receptor internalization defect. We also aimed to examine PB features of a mouse model of WHIM syndrome (Cxcr4+/1013) and examine WHIM syndrome and WHIM mouse PB morphologic changes after CXCR4 antagonist therapy. Carboxy-terminal nonsense/frameshift CXCR4 variants were associated with myelokathectic neutrophil morphology in 32% to 80% (median, 66%) and 4% to 14% (median, 9%) of total neutrophils in the BM and PB, respectively. In contrast, myelokathectic neutrophils were infrequent in 5 missense CXCR4 variants (3 CXCR4D84H and 2 CXCR4S341Y). Compared with neutropenic controls, carboxy-terminal CXCR4 nonsense/frameshift variants were associated with >10% BM or >5% PB myelokathectic neutrophils (100% specific; 100% [BM] or 93% [PB] sensitive), as well as more frequent neutrophil apoptosis (BM, P = .0093; PB, P < .0001), dysmorphic/vacuolated eosinophils (BM, P = .012; PB, P < .0001), neutrophil vacuolization (BM, P < .0001), and nonparatrabecular neutrophil clusters in the BM (P = .0059). BM myeloid hyperplasia occurred in 54% of carboxy-terminal CXCR4 nonsense/frameshift variants and in no controls. BM myelokathectic neutrophil percentage correlated with the functional CXCR4 internalization defect (P ≤ .0042). Like humans, WHIM mice (Cxcr4+/1013) demonstrated circulating myelokathectic-like neutrophils with nuclear hypersegmentation. CXCR4 antagonist therapy in patients with WHIM syndrome (n = 5) and mice increased both morphologically normal and myelokathectic neutrophils in PB. We demonstrated notable genotype-phenotype heterogeneity between CXCR4 variants and myelokathexis, which correlates with functional CXCR4 internalization defect. The morphologic features of WHIM syndrome may be subtle, resulting in misdiagnosis. We described key morphologic features that are useful to facilitate diagnosis.

Keywords: CXCR4; Hypogammaglobulinemia; WHIM syndrome; Warts; immunodeficiency; myelokathexis; neutropenia.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosures

LR, BS, VG, ME and KB have a research agreement with X4 Pharmaceuticals, which is directly related to this work. KZ, CHN, RJ and AT are employees and shareholders of X4 Pharmaceuticals. TM: Advisory boards (Horizon, Chiesi USA and Grifols) in the past 2 years, unrelated to this work. TKT: Advisory boards (Chiesi, X4) and is an X4 site investigator for the Phase 3 WHIM and Phase 3 Chronic neutropenia clinical trials – none are directly related to this work. JRB is on the scientific advisory board and has a research agreement with X4 Pharmaceuticals, which is indirectly related to, and has no conflict with, this work.

References

    1. McDermott DH, Murphy PM. WHIM syndrome: Immunopathogenesis, treatment and cure strategies. Immunol Rev. 2019;287:91–102. doi: 10.1111/imr.12719 - DOI - PubMed
    1. Cohen SB, Fenneteau O, Plouvier E, Rohrlich P-S, Daltroff G, Plantier I, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71. doi: 10.1186/1750-1172-7-71 - DOI - PMC - PubMed
    1. Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39:532–556. doi: 10.1007/s10875-019-00665-w - DOI - PMC - PubMed
    1. Balabanian K, Brotin E, Biajoux V, Bouchet-Delbos L, Lainey E, Fenneteau O, et al. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood. 2012;119:5722–5730. doi: 10.1182/blood-2012-01-403378 - DOI - PubMed
    1. Filippo KD, Rankin SM. CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease. Eur J Clin Invest. 2018;48:e12949. doi: 10.1111/eci.12949 - DOI - PMC - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources